KRN383

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406725

CAS#: 919767-02-5

Description: KRN383 also inhibited the proliferation of the ITD-positive cell lines with IC(50) values of < or =2.9 nM. A single oral administration of 80 mg/kg of KRN383 eradicated ITD-positive xenograft tumors in nude mice and prolonged the survival of SCID mice carrying ITD-positive AML cells. The effectiveness of a single oral dose of KRN383 suggests that it has the potential to be used in a wide variety of clinical regimens, including multicycle and combination therapies.

Chemical Structure

img
KRN383
CAS# 919767-02-5
Handing Instruction

Theoretical Analysis

MedKoo Cat#: 406725
Name: KRN383
CAS#: 919767-02-5
Chemical Formula: C17H17N3O4
Exact Mass: 327.12191
Molecular Weight: 327.33
Elemental Analysis: C, 62.38; H, 5.23; N, 12.84; O, 19.55

Size Price Shipping out time Quantity
Inquire bulk and customized quantity
Pricing updated 2021-03-01. Prices are subject to change without notice.

KRN383 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: KRN383, KRN 383, KRN-383

IUPAC/Chemical Name: 1-(4-((7-hydroxy-6-methoxyquinolin-4-yl)oxy)cyclohexa-1,5-dien-1-yl)urea

InChi Key: FDEJMZJEHJWMRY-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H17N3O4/c1-23-16-8-12-13(9-14(16)21)19-7-6-15(12)24-11-4-2-10(3-5-11)20-17(18)22/h2-4,6-9,11,21H,5H2,1H3,(H3,18,20,22)

SMILES Code: O=C(N)NC1=CCC(OC2=CC=NC3=CC(O)=C(OC)C=C23)C=C1

Appearance:
Solid powder

Purity:
>98%

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 327.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Giles FJ. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting. Leuk Res. 2006 Dec;30(12):1469-70. Epub 2006 May 2. PubMed PMID: 16631251.

2: Nishiyama U, Yoshino T, Ozai M, Yoshioka R, Fujisawa M, Ogasawara Y, Kitahori M, Yoshioka E, Kubo K, Komeno Y, Kurokawa M, Ogawa S, Chiba S, Osawa T, Kuwaki T, Hirai H, Miwa A. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. Leuk Res. 2006 Dec;30(12):1541-6. Epub 2006 Apr 17. Erratum in: Leuk Res. 2007 Oct;31(10):1457. PubMed PMID: 16603240.

img

KRN383

10mg / Not available


Additional Information